Sugi Predict

Sugi Predict / Compounds / SCHEMBL2014792

SCHEMBL2014792

SCHEMBL2014792

O=CCCCCCCCCCCCCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.63
▸ TSHR P16473 2/20 0.63
▸ NFKB1 P19838 1/20 0.63
▸ PMP22 Q01453 1/20 0.63
▸ MAPT P10636 3/20 0.62
▸ ABCC4 O15439 1/20 0.62
▸ PPARG P37231 4/20 0.56
▸ PPARD Q03181 4/20 0.56
▸ PPARA Q07869 4/20 0.56
▸ TERT O14746 3/20 0.56
▸ PTPN1 P18031 3/20 0.56
▸ BLM P54132 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ FABP4 P15090 2/20 0.56
▸ F7 P08709 2/20 0.56
▸ F3 P13726 2/20 0.56
▸ GMNN O75496 1/20 0.56
▸ USP2 O75604 1/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380888 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL258956 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL14798059 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL274867 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL15526298 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL648618 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL1603841 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL1654500 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL17744969 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT
SCHEMBL174463 1.00 LMNA (0.63) LMNATSHRNFKB1PMP22MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551651-B1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA AS (DK) 2024-03-06 — — EP claimed
CN-117384274-A Acylated GLP-1/GLP-2 dual agonists 西兰制药公司 2024-01-12 — — CN claimed
US-20230405087-A9 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA A/S (DK) 2023-12-21 — — US claimed
US-20230192770-A1 COMPSTATIN ANALOGUES AND THEIR MEDICAL USES ZEALAND PHARMA A/S (DK) 2023-06-22 — — US claimed
US-20230000951-A1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA AS (DK) 2023-01-05 — — US claimed
US-11395847-B2 Acylated GLP-1/GLP-2 dual agonists ZEALAND PHARMA A/S (DK) 2022-07-26 — — US claimed
EP-4021921-A1 COMPSTATIN ANALOGUES AND THEIR MEDICAL USES ZP SPV 3 K/S (DK) 2022-07-06 — — EP claimed
CN-114630836-A Compstatin analogs and medical uses thereof 西兰制药第三特殊目的公司 2022-06-14 — — CN claimed
US-20210244798-A9 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA A/S (DK) 2021-08-12 — — US claimed
WO-2021037942-A1 COMPSTATIN ANALOGUES AND THEIR MEDICAL USES ZP SPV 3 K/S (DK) 2021-03-04 — — WO claimed
US-10457714-B2 Acylated glucagon analogues ZEALAND PHARMA A/S (DK) 2019-10-29 — — US claimed
EP-3551651-A1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS Zealand Pharma A/S (DK) 2019-10-16 — — EP claimed
WO-2018104558-A1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA A/S (DK) 2018-06-14 — — WO claimed
WO-2018104561-A1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA A/S (DK) 2018-06-14 — — WO claimed
US-7541430-B2 Peptides for use in treating obesity NOVO NORDISK A/S (DK) 2009-06-02 — — US claimed
US-20070244054-A1 Peptides for use in treating obesity NOVO NORDISK A/S (DK) 2007-10-18 — — US claimed
CN-1784423-A Peptides for use in treating obesity NOVO NORDISK AS (DK) 2006-06-07 — — CN claimed
EP-1625158-A2 PEPTIDES FOR USE IN TREATING OBESITY NOVO NORDISK A/S (DK) 2006-02-15 — — EP claimed
WO-2004099246-A2 PEPTIDES FOR USE IN TREATING OBESITY NOVO NORDISK A/S (DK) 2004-11-18 — — WO claimed
US-5747537-A Method of inhibiting parasitic activity WASHINGTON UNIVERSITY (US) 1998-05-05 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230405087-A9 ACYLATED GLP-1/GLP-2 DUAL AGONISTS GLP1R, GIPR, GPR119 LMNA 2721/4885TSHR 313/4885NFKB1 4088/4885
US-10457714-B2 Acylated glucagon analogues GLP1R, GCGR, GIPR LMNA 4250/4885TSHR 144/4885NFKB1 4587/4885
US-20070244054-A1 Peptides for use in treating obesity NPY4R, GLP1R, NPY1R LMNA 3088/4885TSHR 296/4885NFKB1 2722/4885
US-11395847-B2 Acylated GLP-1/GLP-2 dual agonists GLP1R, GIPR, GPR119 LMNA 2721/4885TSHR 313/4885NFKB1 4088/4885
US-20230000951-A1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS GLP1R, GIPR, GPR119 LMNA 2721/4885TSHR 313/4885NFKB1 4088/4885
US-20210244798-A9 ACYLATED GLP-1/GLP-2 DUAL AGONISTS GLP1R, GIPR, GPR119 LMNA 2721/4885TSHR 313/4885NFKB1 4088/4885
US-20230192770-A1 COMPSTATIN ANALOGUES AND THEIR MEDICAL USES C1QBP, C9, VIP LMNA 1380/4885TSHR 1041/4885NFKB1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.